Skip to content

Study Details

MEDI3506: A Study Drug for People who had Chronic Obstruction Pulmonary Disease (COPD) with a History of Severe COPD

(IRB#: IRB_00153167)

Chronic Obstruction Pulmonary Disease (COPD) is a type of progressive lung disease with symptoms such as difficulty breathing. MEDI3506 is a study drug to help people with COPD. Research is needed to learn the safety and effectiveness of the drug. The information we gain may aid future patients.


  • All genders
  • Over 18 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: Over 18 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  •  40 years of age
  • Diagnosis of COPD for at least 1 year
  • Severe COPD symptoms within the past year
  • Use of COPD inhaled treatment for COPD in the past 3 months
  • Former or current smoker

Exclusion Criteria

  • Other lung diseases such as active lung infection, pulmonary fibrosis, cystic fibrosis, etc.
  • COPD that worsens within the past 2 weeks required taking medicine and/or going to the hospital
  • Active vaping of any products in the past 6 months
  • Ongoing COVID-19 infection or any serious COVID-19 illness in the prior 6 months, such as COVID-19 pneumonia, etc.

Will I be paid for my time?


For more information contact:

Andriea Smith


IRB#: IRB_00153167

PI: Cheryl Pirozzi

Department: PULMONARY

Approval Date: 2022-08-24 06:00:00

Specialties: Pulmonary

Last Updated: 6/8/23